Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Depreciation and Depletion (2017 - 2021)

Edesa Biotech's Depreciation and Depletion history spans 5 years, with the latest figure at $1.9 billion for Q3 2021.

  • For Q3 2021, Depreciation and Depletion fell 80.12% year-over-year to $1.9 billion; the TTM value through Sep 2021 reached $8.3 billion, down 28.21%, while the annual FY2024 figure was $8702.0, 101.06% up from the prior year.
  • Depreciation and Depletion for Q3 2021 was $1.9 billion at Edesa Biotech, down from $6.4 billion in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $9.6 billion in Q3 2020 and bottomed at $412.0 in Q4 2018.
  • The 5-year median for Depreciation and Depletion is $24618.0 (2018), against an average of $1.4 billion.
  • The largest annual shift saw Depreciation and Depletion plummeted 99.16% in 2018 before it skyrocketed 94902234.44% in 2020.
  • A 5-year view of Depreciation and Depletion shows it stood at $49309.0 in 2017, then tumbled by 99.16% to $412.0 in 2018, then soared by 483.25% to $2403.0 in 2019, then tumbled by 32.63% to $1619.0 in 2020, then soared by 117912191.54% to $1.9 billion in 2021.
  • Per Business Quant, the three most recent readings for EDSA's Depreciation and Depletion are $1.9 billion (Q3 2021), $6.4 billion (Q2 2021), and $1619.0 (Q1 2021).